AbbVie | ABBV - Selling And Administration Expenses

Stock Price
225.64
Daily Change
2.63 1.18%
Monthly
2.48%
Yearly
18.67%
Q1 Forecast
216.14

AbbVie reported $3.25B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Abbott USD 3.13B 125M Dec/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eisai JPY 103.86B 3.7B Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
J&J USD 6.75B 831M Dec/2025
Medtronic 2.97B 159M Sep/2025
Merck USD 2.63B 0 Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.29B 221M Dec/2024
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025
Zoetis USD 579M 29M Sep/2025